Aquestive Therapeutics (AQST) Projected to Release Quarterly Earnings on Tuesday

Aquestive Therapeutics (NASDAQ:AQST) will likely be releasing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.10) per share and revenue of $11.02 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. On average, analysts expect Aquestive Therapeutics to post ($0.50) EPS for the current fiscal year and ($0.50) EPS for the next fiscal year.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $3.89 on Monday. The business’s 50 day moving average is $4.66 and its 200 day moving average is $4.20. The company has a market capitalization of $488.24 million, a PE ratio of -5.98 and a beta of 1.49. Aquestive Therapeutics has a 12-month low of $2.93 and a 12-month high of $6.87.

Insider Buying and Selling

In related news, CEO Daniel Barber sold 25,000 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $4.22, for a total transaction of $105,500.00. Following the sale, the chief executive officer owned 627,317 shares of the company’s stock, valued at $2,647,277.74. This represents a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total transaction of $45,675.00. Following the sale, the insider directly owned 235,689 shares in the company, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 58,750 shares of company stock valued at $271,675 over the last quarter. Corporate insiders own 6.81% of the company’s stock.

Wall Street Analyst Weigh In

AQST has been the subject of a number of research reports. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price target on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 15th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Friday, October 16th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.60.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.